breast cancer: palbociclib in later lines
Published 5 years ago • 179 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
1:56
vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
6:47
palbociclib: single-agent or in combination for the treatment of breast cancer
-
13:22
palbociclib and breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
2:56
parsifal-long: fulvestrant and palbociclib vs letrozole and palbociclib
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:53
palbociclib & fulvestrant for breast cancer
-
1:59
palbociclib: an exciting new option in breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
8:25
paloma-1 study of palbociclib in er , her2-, breast cancer
-
3:02
paloma-3: palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
-
1:56
palmares-2: comparing first-line palbociclib, ribociclib, or abemaciclib in hr /her2- abc